AOA Dx
operating company · company profileDenver · 17 people tracked
Find your way into AOA Dx
Sign up to see every warm intro you have to AOA Dx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the AOA Dx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
AOA Dx invests in advancing early cancer detection through multi-omic blood-based diagnostics. The company leverages liquid chromatography-mass spectrometry technology and machine learning to identify tumor-associated gangliosides as biomarkers for detecting ovarian cancer at early stages. The approach combines scientific collaboration with academic institutions, peer-reviewed research validation, and clinical studies to establish real-world diagnostic efficacy.
Source: firm website, verified Nov 8, 2026.
Team · 17 people
from the firm's websiteBusiness leader with a track record of launching UK medical device and diagnostics sales companies, focused on commercializing products across European healthcare markets in obstetrics and gynecology. He holds a degree and MSc from the University of Southampton and University College London.
Co-founder and COO of AOA Dx, overseeing operations and development of the Omira Discovery early cancer detection platform. Named to Inc.'s 2022 Female Founders 100 List, she has experience with US FDA submissions and launching diagnostics globally.
Co-founder and CEO of AOA Dx, a leader in women's health and diagnostics recognized in Inc.'s 2022 Top 100 Female Founders for her work in ovarian cancer diagnosis. She has global experience building and leading diagnostics organizations through strategic exits and holds a degree in Economics and International Relations from Boston University.
Chief Scientific Officer with nearly two decades leading R&D teams on oncology diagnostic assays, including IHC companion diagnostics, NGS panels, and multi-omic assays with machine learning. She holds a PhD from Northeastern University with postdoctoral work at the University of Arizona.
Diagnostics commercialization leader with over 20 years of experience launching oncology tests, leading product strategy, market access, and reimbursement at AOA. He previously held roles at Arima Genomics, Veracyte, Caris Life Sciences, and Ventana Medical Systems, and holds a BS from Georgia Tech and an MBA from Duke.
Bioanalytical and proteomics expert with over 25 years in mass spectrometry-based diagnostics. He holds a PhD from the University of Oregon and has held roles at Quest Diagnostics, Cleveland HeartLab, Ultragenyx, and Cedars-Sinai.
Leader with over 25 years in biostatistics, clinical development, and personalized medicine, instrumental in developing Oncotype Dx. He has founded multiple clinical diagnostics companies and advises biopharma, diagnostics, and VC firms.
Clinical operations executive with over 15 years leading global clinical programs across biotech, diagnostics, and medical devices, overseeing AOA's OVERT study. She holds a Master of Science from Saint Louis University and PMP and CCRP certifications.
Diagnostics development leader with over 12 years in IVD assay development, design control, and liquid biopsy programs, leading late-stage IVD development at AOA. She holds degrees from the University of Pennsylvania and a PhD from MIT, and previously worked at Thermo Fisher, PGDx, Precision for Medicine, and Exact Sciences.
Computational biologist and biostatistician with expertise in genomics and microbiome science, founder of Resphera Biosciences. He holds a PhD in Applied Mathematics from the University of Maryland.
Founding and Managing Partner of Easton Capital Investment Group with roughly 20 years of experience; previously founder of Security Pacific Capital Investors and a partner at E.M. Warburg, Pincus. He has invested in over 100 transactions and holds degrees from Yale College and Yale Law School.
Board-certified gynecologic oncologist and Assistant Clinical Professor at UT Health San Antonio, with expertise in advanced pelvic surgery and research in cancer care cost-effectiveness and financial toxicity. She advises AOA on evidence-based care and oncology innovation.
Physician-scientist specializing in gynecologic oncology and early cancer detection, trained at Harvard College and Vanderbilt with residency and fellowships at Brigham and Women's Hospital. He is a practicing gynecologic oncologist at Cleveland Clinic.
Pioneer in lipidomics with over two decades of experience across academia, biotech, and regulatory science; President of the International Lipidomics Society and co-founder of the Lipidomics Standards Initiative. He earned his PhD from the Technical University of Dresden and founded Lipidomics Consulting Ltd.
Founder and former CEO of nVision Medical, acquired by Boston Scientific in 2018, and Y Combinator's first healthcare and biotech partner. She serves on several boards and has extensive experience in product development, funding, and commercialization.
Translational medicine scientist with over 200 publications and 21 patents, focused on targeting gangliosides used in cancer diagnosis, prognosis, and therapy. He is based at McGill University and the Lady Davis Institute in Montreal.
Diagnostics R&D leader with a background in assay development and analytical chemistry, leading AOA's R&D team in building analytical capabilities and advancing the Omira OC product. He previously worked at Ventana Medical Systems, PGDx, and Exact Sciences.
Founder mafia
3 people who came through AOA Dx went on to found or lead other companies.
Frequently asked questions
- What sectors does AOA Dx focus on?
- AOA Dx focuses on AI & Machine Learning, Biotech, Digital Health, FemTech, Medical Devices.
- Where is AOA Dx located?
- AOA Dx is headquartered in Denver, US.
Media · Podcasts & interviews
featuring the teamAOA Dx: A breakthrough in early ovarian cancer detection
Dr Fiona Pathiraja-Møller · Oriana Papin-Zoghbi · linkedin.com
Transforming Women's Health Through Innovation with Oriana Papin-Zoghbi, CEO & Co-Founder of AOA Dx
Building Biotechs Podcast by Recruitomics · Oriana Papin-Zoghbi
Meet YC: Interview with Oriana Papin-Zoghbi of AOA Dx (YC S21)
Y Combinator · Oriana Papin-Zoghbi
AOA Dx is Attempting To Diagnose Ovarian Cancer
FemTech Focus · Oriana Papin-Zoghbi
Similar investors
Future Positive Capital is a venture firm that backs entrepreneurs building companies aimed at solving universal challenges at planetary scale across science and technology.
MedMountain Ventures (MMV) is a physician-led, early-stage healthcare venture capital firm founded by board-certified physicians and healthcare operators that backs companies improving patient outcomes and transforming care delivery.
SV Tech Ventures is a Palo Alto-based venture capital firm backing early-stage startups developing advanced technologies with high barriers to entry.
Industrifonden is Sweden's evergreen venture capital fund, backing scalable innovations from first check to global scale, with a focus on Sweden and the wider Nordic region.
Wavemaker 360 (Wavemaker Three-Sixty Health) is a healthcare-focused venture capital firm backing entrepreneurs seeking to disrupt and transform the healthcare industry.




















